Journal of Hepatology
Volume 47, Issue 4 , Pages 588-597 , October 2007

Best practice in the treatment of chronic hepatitis B: A summary of the European Viral Hepatitis Educational Initiative (EVHEI)

References 

  1. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431–435
  2. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989;2:588–591
  3. Chu CM, Karayiannis P, Fowler MJ, Monjardino J, Liaw YF, Thomas HC. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology. 1985;5:431–434
  4. Manno M, Cammà C, Schepis F, Bassi F, Gelmini R, Giannini F, et al. Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years. Gastroenterology. 2004;27:756–763
  5. Bortolotti F, Guido M, Bartolacci S, Cadrobbi P, Crivellaro C, Noventa F, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology. 2006;43:556–562
  6. Liaw Y-F, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005;25:472–489
  7. Keeffe EB, Dieterich DT, Han S-HB, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006;4:936–962
  8. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
  9. Nguyen MH, Trinh H, Garcia RT, Ahmed A, Keeffe E. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation. Hepatology. 2005;42:593A
  10. Lai M, Hyatt B, Afdhal N. Role of liver biopsy in patients with normal ALT and high HBV DNA. Hepatology. 2005;42:720A
  11. Chevaliez S, Germanidis G, Roudot-Thoraval F, Bouvier-Alias M, Brillet R, Guerre F, et al. Diagnostic and prognostic value of virological parameters in a large homogenous cohort of patients with HBe-negative genotype D-related chronic hepatitis B. Hepatology. 2006;44:254A
  12. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HbeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422–1427
  13. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001;34:306–313
  14. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA. 1996;93:4398–4402
  15. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800–807
  16. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–2695
  17. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808–816
  18. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–117
  19. Rizzetto M, Tassopoulos NC, Goldin RD, Esteban R, Santantonio T, Heathcote EJ, et al. Extended lamivudine treatment in patients with HbeAg-negative chronic hepatitis B. J Hepatol. 2005;42:173–179
  20. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206–1217
  21. Hadziyannis S, Tassopoulos N, Chang TT, Heathcote J, Kitis G, Rizzetto M, et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of treatment. Hepatology. 2005;42:754A
  22. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–1010
  23. Shouval D, Akarca US, Hatzis G, Kitis G, Lai CL, Cheinquer H, et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(−) chronic hepatitis B patients (Study ETV-027). J Hepatol. 2006;44:S21–S22
  24. Lai C-L, Gane E, Hsu C-W, Thongsawat S, Wang Y, Chen Y, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine. Hepatology. 2006;44:222A
  25. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
  26. Hadziyannis SJ, Sevastianos V, Rapti IN, Tassopoulos N. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. Hepatology. 2006;44:231A

☆ This article is based on the proceedings of the 2nd European Viral Hepatitis Educational Initiative (EVHEI) workshop held in Frankfurt, Germany, on 23–24 November 2006. The EVHEI faculty includes: Howard Thomas, MD (Chair), Ferrucio Bonino, MD, Graham Foster, MD, Stephanos Hadziyannis, MD, Michael Manns (Co-chair), MD, Patrick Marcellin, MD, Rafael Esteban-Mur, MD, Jean-Michel Pawlotsky, MD, Christian Trépo, MD, Ran Tur-Kaspa, MD, and Fabien Zoulim, MD.

☆☆ The author declares that the manuscript was developed by Howard C. Thomas (H.C.T.) in conjunction with International Medical Press. EVHEI is run by International Medical Press and is in receipt of educational grants from BMS and Valeant. The article is based on a paper presented at the meeting by H.C.T. The participants travel and accommodation were supported by the meeting’s sponsors. The author attends the International Advisory Boards of BMS, Genome Sciences, Roche, Gilead and Idenix/Novartis.

PII: S0168-8278(07)00413-8

doi: 10.1016/j.jhep.2007.07.017

Journal of Hepatology
Volume 47, Issue 4 , Pages 588-597 , October 2007

Article Tools

* Image Usage & Resolution